A PYMNTS Company

Former Novartis Executive Sentenced to Probation for Role in Generic Drug Price-Fixing Scheme

By  |  May 16, 2024

Hector Kellum, a former senior executive of Novartis unit Sandoz, has been sentenced to one year of probation by a U.S. court. Kellum had previously pleaded guilty to participating in a scheme aimed at fixing prices for generic medicines.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The case, which dates back to 2020, unfolded in Philadelphia federal court, where Kellum admitted to his involvement in manipulating the prices of clobetasol and nystatin triamcinolone cream. Clobetasol is commonly prescribed to treat eczema and psoriasis, while nystatin triamcinolone cream is used as an anti-fungal medication.

    According to reports by Reuters, Kellum’s guilty plea also involved an agreement to cooperate with the government’s broader investigation into antitrust violations within the generic drug industry. Prosecutors revealed that one of Kellum’s alleged collaborators in the scheme was Ara Aprahamian, a former sales and marketing executive at Taro Pharmaceutical Industries, who faced charges related to price-fixing and bid-rigging.

    Despite the allegations against Aprahamian, prosecutors requested the dismissal of the case last year. Aprahamian had pleaded not guilty to charges, including price-fixing and bid-rigging, in Philadelphia federal court.

    Source: Reuters